1 not yet recruiting, 1 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Not yet recruiting 1, Unknown 1 |
Follow COVID - 19: new trials by email Literature Review of COVID - 19 trials Research Report on COVID - 19
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dapagliflozin for Long COVID Syndrome Dapagliflozin (DAPA), Placebo - COVID - 19, Long COVID Syndrome | Phase 3 | Not yet recruiting | Ottawa Heart Institute Research Corporation | 192 | 2026-12-01 | 2026-10-30 |
| Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus hydroxychloroquine in combination with camostat mesylate, Hydroxychloroquine in combination of Azithromycin - COVID - 19 | Phase 3 | Unknown | Sheba Medical Center | 250 | 2020-04-11 | 2020-04-21 |
COVID-19 (2)
Coronaviridae Infections (2) · Coronavirus Infections (2) · Infections (2) · Lung Diseases (2) · Nidovirales Infections (2) · Pneumonia (2) · Pneumonia, Viral (2) · RNA Virus Infections (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Virus Diseases (2)
Hydroxychloroquine (1) · camostat (1) · dapagliflozin (1)
Ottawa Heart Institute Research Corporation (1) · Sheba Medical Center (1)
Canada (1) · Israel (1)